Table 2.
Associations between Discoid Lupus and other ACR Criteria for SLE as well as End-Stage Renal Disease
| SLE Manifestation (n=positive finding out of 1043) |
SLE without DLE (n=926) n (%) |
SLE with DLE (n=117) n (%) |
Unadjusted OR (95% CI) |
Adjusted OR* (95% CI) |
Adjusted OR** (95% CI) |
|---|---|---|---|---|---|
| Anti-Smith | 201 (21.7) | 45 (38.5) | 2.25 (1.50–3.38) | 2.27 (1.50–3.45) | 2.41 (1.58– 3.69) |
| Photosensitivity | 374 (40.4) | 60 (51.3) | 1.55 (1.06–2.28) | 1.71 (1.15–2.55) | 1.63 (1.09– 2.44) |
| Leukopenia | 301 (32.5) | 50 (42.7) | 1.55 (1.05–2.29) | 1.50 (1.01–2.24) | 1.55 (1.03– 2.32) |
| Pleuritis | 349 (37.7) | 31 (26.5) | 0.59 (0.39–0.92) | 0.56 (0.36–0.88) | 0.56 (0.36–0.87) |
| Arthritis | 738 (79.7) | 79 (67.5) | 0.53 (0.35–0.80) | 0.51 (0.33–0.79) | 0.49 (0.31–0.76) |
| Lupus Nephritis | 281 (30.3) | 38 (32.5) | 1.10 (0.73–1.66) | 1.09 (0.71–1.68) | 1.33 (0.83–2.14) |
| Pericarditis | 112 (12.1) | 10 (8.6) | 0.68 (0.35–1.34) | 0.68 (0.34–1.36) | 0.68 (0.34–1.36) |
| Proteinuria | 256 (27.7) | 27 (23.1) | 0.78 (0.50–1.23) | 0.70 (0.43–1.13) | 0.77 (0.47–1.27) |
| Casts | 117 (12.6) | 9 (7.7) | 0.56 (0.28–1.17) | 0.53 (0.26–1.09) | 0.57 (0.27–1.20) |
| End-Stage Renal Disease | 48 (5.1) | 7 (6.0) | 1.16 (0.51–2.64) | 0.96 (0.41– 2.22) | 1.24 (0.50–3.05) |
| Oral ulcers | 240 (25.9) | 37 (31.6) | 1.32 (0.87–2.00) | 1.35 (0.88–2.07) | 1.32 (0.86–2.03) |
| Malar Rash | 406 (43.8) | 46 (39.3) | 0.82 (0.56–1.23) | 0.86 (0.57–1.30) | 0.88 (0.58–1.32) |
| Seizure | 100 (10.8) | 14 (12) | 1.12 (0.61–2.03) | 1.14 (0.62–2.09) | 1.20 (0.65–2.21) |
| Psychosis | 16 (1.7) | 3 (2.6) | 1.50 (0.43–5.21) | 1.45 (0.41–5.14) | 1.50 (0.42–5.38) |
| Anemia | 181 (19.5) | 26 (22.2) | 1.17 (0.74–1.87) | 1.12 (0.69–1.80) | 1.15 (0.71–1.86) |
| Lymphopenia | 340 (36.7) | 51 (43.6) | 1.33 (0.90–1.96) | 1.32 (0.88–1.97) | 1.38 (0.91–2.08) |
| Thrombocytopenia | 110 (11.9) | 18 (15.4) | 1.35 (0.79–2.31) | 1.45 (0.83–2.54) | 1.54 (0.87–2.71) |
| Anti-dsDNA | 610 (65.9) | 83 (70.9) | 1.27 (0.83–1.93) | 1.25 (0.81–1.93) | 1.33 (0.86–2.07) |
| Antiphospholipid antibodies | 225 (24.3) | 24 (20.5) | 0.80 (0.50–1.29) | 0.85 (0.52–1.37) | 0.87 (0.54–1.43) |
OR= odds ratio
OR= Multivariable logistic regression analyses modeling the odds ratio of DLE associated with each SLE manifestation or laboratory finding individually, adjusted for age at diagnosis, sex, race/ethnicity, disease duration
OR= Multivariable logistic regression analyses modeling the odds ratio of DLE associated with each SLE manifestation or laboratory finding individually, adjusted for age at diagnosis, sex, race/ethnicity, disease duration, ever medication use: steroids (ever/never), hydroxycholorquine (ever/never), immunosuppressives (azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, systemic corticosteroids – ever/never)